Summary

Tralokinumab, a human immunoglobulin-G4 monoclonal antibody, potently and specifically neutralizes interleukin (IL)-13, a pleiotropic cytokine thought to be a central mediator of asthma [Mitchell J et al. Curr Opin Investig Drugs 2010]. This article presents the overall results from A Phase 2b, Randomized, Double-Blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma [NCT01402986; Brightling CE et al. Am J Crit Care Med 2014].